Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations [1]

New England Journal of Medicine

Volumn 357, Issue 15, 2007, Pages 1555-1556

  Goodwin, Pamela J ^a   Phillips, Kelly Anne ^b   West, Dee W ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c NORTHERN CALIFORNIA CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; DNA STRAND BREAKAGE; GENE MUTATION; HUMAN; LETTER; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; MUTATION; NOTE; PATHOLOGY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; NEOPLASM STAGING; PROGNOSIS;

EID: 35248877133     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc072301     Document Type: Letter

References (5)

1. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115-23.
2. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? J Clin Oncol 1999;17:3653-63.
3. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002;95:2068-75.
4. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
5. Bryski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (in press).